Impact of Race/Ethnicity on Platelet Function
The effects of race/ethnicity on platelet function and response to antiplatelet agents will be assessed using 125 healthy subjects, 250 coronary heart disease patients treated with aspirin, and 250 coronary heart disease patients treated with aspirin and a P2Y12 receptor antagonist, clopidogrel or prasugrel. A minimum of 25 healthy people, 50 people taking only aspirin, and 50 people taking aspirin and clopidogrel/prasugrel will be recruited for at least 5 racial/ethnic groups.
Coronary Heart Disease
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||Impact of Race/Ethnicity on Platelet Function|
- Platelet reactivity as measured by platelet function tests [ Time Frame: Platelet reactivity will be assessed at baseline only. No follow-up will occur ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood or saliva samples will be collected for DNA extraction and genotyping of CYP2C19 and other relevant genes.
|Study Start Date:||June 2010|
|Study Completion Date:||March 2013|
|Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01168622
|United States, Nebraska|
|University of Nebraska Medical Center|
|Omaha, Nebraska, United States, 68198|
|Principal Investigator:||Julie H Oestreich, PharmD, PhD||University of Nebraska|